Article citationsMore>>

Seban, R., Arnaud, E., Loirat, D., Cabel, L., Cottu, P., Djerroudi, L., et al. (2023) [18F]FDG PET/CT for Predicting Triple-Negative Breast Cancer Outcomes after Neoadjuvant Chemotherapy with or without Pembrolizumab. European Journal of Nuclear Medicine and Molecular Imaging, 50, 4024-4035.
https://doi.org/10.1007/s00259-023-06394-y

has been cited by the following article:

• TITLE: The Evolving Role of FDG-PET/CT in the Management of Cervical Cancer

  AUTHORS: Yuxin Zheng, Gang Cheng

  KEYWORDS: Cervical Cancer, 18F-FDG PET/CT, Clinical Management

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.14 No.3, March 18, 2026

  ABSTRACT: With the advancement of imaging technologies, the application of 18F-FDG PET/CT in the diagnosis and management of cervical cancer has garnered increasing attention. This article aims to review the clinical progress of PET/CT in the management of patients with cervical cancer. PET/CT has been widely used to assess lymph node status and distant metastases, and it is recommended for comprehensive staging in patients with locally advanced cervical cancer (FIGO stage ≥ IB3), enabling more rational planning and individualized treatment adjustments. Metabolic information from both the primary tumor and lymph nodes can be utilized for treatment response evaluation, prognosis prediction, and recurrence monitoring, ultimately helping to optimize the timing of interventions and improve survival outcomes. Meanwhile, the distribution of 18F-FDG uptake within the tumor can partially reflect tumor heterogeneity and provide complementary information to conventional semi-quantitative parameters. However, the clinical value of PET/CT in the management of patients with cervical cancer remains to be further validated.